ABLYNX SELECTS GPCR TARGETING DEVELOPMENT CANDIDATE, ANNOUNCES NEW DATA ON ALTERNATIVE ROUTES OF DELIVERY FOR NANOBODIES AND PROVIDES AN R&D UPDATE
(Thomson Reuters ONE) - GHENT, Belgium, 11 February 2010 - Ablynx [Euronext Brussels: ABLX] announcedtoday that it has selected a new GPCR targeting development candidate, ALX-0651,an anti-CXCR4 Nanobody which is being developed for hematopoietic stem cellmobilisation. The Company is also releasing new data on pulmonary to systemicadministration and needle-free administration of Nanobodies. Ablynx will presentan update of its therapeutic pipeline and its recent technology advances at itsR&D Investor Update in New York, USA tomorrow at 8.00 a.m. EST.Selection of GPCR targeting development candidateIn January 2009, Ablynx successfully generated functional Nanobodies againstCXCR4, a clinically validated GPCR. Today, the Company has announced that itscriteria for preclinical development have been reached and that Ablynx willprogress this compound named ALX-0651, towards the clinic. CXCR4 plays animportant role in cell movement, tumor growth and metastasis.New data on alternative route of delivery and R&D updateAblynx has announced additional data on the use of a needle-free device fortransdermal delivery and data on the administration of Nanobodies systemicallyvia the pulmonary route.Specifically, the Company has successfully demonstrated that Nanobodies can bemade as a solid formulation in clinically relevant amounts. Furthermore, whenadministered via a needle-free route, they have shown a similar pharmacokinetic(PK) profile compared with subcutaneously injected Nanobodies.In addition to previous data showing that Nanobodies can be detected in thesystemic circulation following delivery to the lungs, Ablynx has nowdemonstrated dose-dependent systemic bioavailability and functionality forNanobodies delivered via the intrapulmonary route. The data indicate that theycan survive the lung environment and can then be detected systemically withintact biological activity. Ablynx continues to investigate new routes ofadministration including oral to systemic, ocular and other forms of transdermaldelivery."In the last twelve months we have made significant progress in advancing bothour therapeutic pipeline and Nanobody-based technology platform," commented DrEdwin Moses, CEO and Chairman of Ablynx. -ends-For more information, please contact:College Hill Life Sciences - for International media enquiries:Sue Charles, Justine Lamondt: +44 (0)20 7866 7857f: +44 (0)20 7866 7900e: ablynx(at)collegehill.com
Unternehmensinformation / Kurzprofil:
Datum: 11.02.2010 - 18:00 Uhr
Sprache: Deutsch
News-ID 12380
Anzahl Zeichen: 0
contact information:
Town:
Ghent
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 155 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"ABLYNX SELECTS GPCR TARGETING DEVELOPMENT CANDIDATE, ANNOUNCES NEW DATA ON ALTERNATIVE ROUTES OF DELIVERY FOR NANOBODIES AND PROVIDES AN R&D UPDATE"
steht unter der journalistisch-redaktionellen Verantwortung von
Ablynx (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
